Beta2-Adrenoceptor Agonists in Parkinson’s Disease and Other Synucleinopathies
Evidence supporting the use of β2AR agonists in synucleinopathies is rapidly growing. Findings come from different scientific approaches. Molecular and immunological data suggest that adrenergic stimulation may decrease both α-synuclein (α-syn) deposition and pro-inflammatory/neurotoxic molecules release. Small open label clinical trials including a total number of 25 Parkinson’s disease (PD) patients, in which the β2AR agonist salbutamol was added to levodopa, suggest a promising symptomatic benefit. In line with these findings, epidemiological studies investigating the risk of PD development suggest that long term exposure to the agonist salbutamol might be protective, while the antagonist propranolol possibly detrimental. Nonetheless, in both lines of investigation the studies performed so far present important limitations. On the clinical side, large randomized controlled trials are lacking, whereas on the epidemiological side the presence of co-morbid conditions (i.e. smoking and essential tremor) potentially influencing PD risk should taken into consideration. In summary, it is our opinion that β2AR stimulation in synucleinopathies has a rationale and therefore merits further investigation.
KeywordsParkinson’s disease Immune system Adrenergic system beta2 adrenergic agonists Alpha-synuclein
This study was funded by the AGING PROJECT – Department of Excellence – Università del Piemonte Orientale.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- Ağaç D, Estrada LD, Maples R, Hooper LV , Farrar JD. (2018). The β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion Brain Behav Immun. https://doi.org/10.1016/j.bbi.2018.09.004
- Arango V, Ernsberger P, Reis DJ, Mann JJ (1990) Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res 516:113–121Google Scholar
- Cappellano G, Carecchio M, Fleetwood T, Magistrelli L, Cantello R, Dianzani U et al (2013) Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis 21:89–107Google Scholar
- Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F, Lecchini S (2007) Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109:632–642CrossRefGoogle Scholar
- Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, Shetty BLD, Lu Y, Estes KA, Standaert DG, Heinrichs-Graham E, Larson LA, Meza JL, Follett M, Forsberg E, Siuzdak G, Wilson TW, Peterson C, Mosley RL (2017) Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1clinical Parkinson’s disease. Npj Parkinsons disease 3:10. https://doi.org/10.1038/s41531-017-0013-5 CrossRefGoogle Scholar
- Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society UPDRS revision task force. Movement Disorder Society sponsored revision of the unified Parkinson’s disease rating scale (MDSUPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129CrossRefGoogle Scholar
- Kustrimovic N, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Comi C, Mauri M, Minafra B, Riboldazzi G, Sanchez-Guajardo V, Marino F, Cosentino M (2016) Dopaminergic receptors on CD4+ T naive and memory lymphocytes correlate with motor impairment in patients with Parkinson's disease. Sci Rep 6:33738CrossRefGoogle Scholar
- Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Minafra B, Riboldazzi G, Sturchio A, Mauri M, Bono G, Marino F, Cosentino M (2018) Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflammation 15:205CrossRefGoogle Scholar
- Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, Liong C, McMurtrey C, Hildebrand WH, Mao X, Dawson VL, Dawson TM, Oseroff C, Pham J, Sidney J, Dillon MB, Carpenter C, Weiskopf D, Phillips E, Mallal S, Peters B, Frazier A, Lindestam Arlehamn CS, Sette A (2017) T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546:656–661CrossRefGoogle Scholar
- Tank AW, Wong DL (2015) Peripheral and central effects of circulating cathecolamines. Compr Physiol 5:1–15Google Scholar